Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure - Université de Lorraine Access content directly
Journal Articles Clinical Research in Cardiology Year : 2022

Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure

Chim Lang
  • Function : Author

Abstract

Background Few data are available regarding changes in mitral regurgitation (MR) severity with guideline-recommended medical therapy (GRMT) in heart failure (HF). Our aim was to evaluate the evolution and impact of MR after GRMT in the Biology study to Tailored treatment in chronic heart failure (BIOSTAT-CHF). Methods A retrospective post-hoc analysis was performed on HF patients from BIOSTAT-CHF with available data on MR status at baseline and at 9-month follow-up after GRMT optimization. The primary endpoint was a composite of all-cause death or HF hospitalization. Results Among 1022 patients with data at both time-points, 462 (45.2%) had moderate-severe MR at baseline and 360 (35.2%) had it at 9-month follow-up. Regression of moderate-severe MR from baseline to 9 months occurred in 192/462 patients (41.6%) and worsening from baseline to moderate-severe MR at 9 months occurred in 90/560 patients (16.1%). The presence of moderate-severe MR at 9 months, independent from baseline severity, was associated with an increased risk of the primary endpoint (unadjusted hazard ratio [HR], 2.03; 95% confidence interval [CI], 1.57–2.63; p < 0.001), also after adjusting for the BIOSTAT-CHF risk-prediction model (adjusted HR, 1.85; 95% CI 1.43–2.39; p < 0.001). Younger age, LVEF ≥ 50% and treatment with higher ACEi/ARB doses were associated with a lower likelihood of persistence of moderate-severe MR at 9 months, whereas older age was the only predictor of worsening MR. Conclusions Among patients with HF undergoing GRMT optimization, ACEi/ARB up-titration and HFpEF were associated with MR improvement, and the presence of moderate-severe MR after GRMT was associated with worse outcome.
Fichier principal
Vignette du fichier
Pagnesi2022_Article_ClinicalImpactOfChangesInMitra.pdf (1.31 Mo) Télécharger le fichier
392_2022_1991_MOESM1_ESM.docx (8.4 Mo) Télécharger le fichier
392_2022_1991_MOESM1_ESM.pdf (901.32 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03613682 , version 1 (18-03-2022)

Licence

Attribution

Identifiers

Cite

Matteo Pagnesi, Marianna Adamo, Iziah E. Sama, Stefan D. Anker, John G. Cleland, et al.. Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clinical Research in Cardiology, 2022, ⟨10.1007/s00392-022-01991-7⟩. ⟨hal-03613682⟩
23 View
44 Download

Altmetric

Share

Gmail Facebook X LinkedIn More